Curis Lifesciences Limited IPO
Curis Lifesciences Limited IPO
Curis Lifesciences Limited IPO
₹ 256000 / 2000 Shares Shares
Minimum Investment
Curis Lifesciences Limited IPO
Issues Price
₹120-128 per equity share
Curis Lifesciences Limited IPO
Open Date
07 Nov 2025
Close Date
11 Nov 2025
Lot Size
1000
Min. Investment
₹ 256000
Issue Price
₹120-128
Listing Date
14 Nov 2025
Issues Size
21,50,000 shares(aggregating up to ₹27.52 crore)
Face Value
₹10 Per Equity Share
Total Shares Offered
2000 Shares
Offered To Public
2000 Shares
Curis Lifesciences Limited IPO
Established in 2010, Curis Lifesciences Limited is a pharmaceutical company specializing in the development, manufacturing, and distribution of a diverse range of products. The company manufactures pharmaceutical products both internationally and nationally on a loan license or on a contract basis, and for own brand marketing.The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya. Curis Lifesciences specializes in the development, manufacturing, and distribution of a broad array of pharmaceutical products that include: General pharmaceutical tablets and capsules Oral liquids External preparations Sterile ophthalmic ointments The firm has a state-of-the-art manufacturing facility in Sanand, Gujarat, operating under strict quality control measures to ensure the safety and efficacy of its products.The company offers different pharmaceutical formulations and products made on a contract basis.They provide tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. As of June 30, 2024, the company has 93 permanent employees.
Founded In
2020
Managing Director
Dharmesh Dasharathbhai Patel
Parent Organization
Curis Lifesciences Limited IPO
Application for Curis Lifesciences Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Individual (min) | ₹120-128 | ₹2,56,000 |
| Individual(max) | ₹120-128 | ₹2,56,000 |
| SHNI(min) | ₹120-128 | ₹3,84,000 |
| SHNI(max) | ₹120-128 | ₹8,96,000 |
| BHNI(min) | ₹120-128 | ₹10,24,000 |
Apply for all eligible candidates, Curis Lifesciences Limited IPO.
Open On12 Dec 2025
Close On16 Dec 2025
Price Range₹2061-2165
Testimonial
Genuine Review Form Statisifed Customers
Navigating investments from Canada was overwhelming until I used KSquare’s NRI services. They simplified the entire process beautifully.
KSquare’s team explained everything clearly. I never thought borrowing against my mutual funds would be this easy.
KSquare’s service was fast, transparent, and easy to follow. Perfect for someone like me who needed quick access to funds.
KSquare makes it simple to understand which NFO suits you. Their comparisons and insights saved me hours of research. Totally recommend it!
KSquare’s pension guidance was much needed. Their team helped me select the right NPS tier and gave detailed explanations.
I've explored several NFOs through KSquare, and their consistent communication builds trust. It’s great having expert updates every step of the way.
I needed urgent cash flow and didn’t want to redeem my funds. KSquare had the perfect solution. Very helpful service!
KSquare helped me invest in Indian markets with zero stress. Their NRI Corner is truly designed for people living abroad.
KSquare offers outstanding NFO briefings that help investors understand the market fit. They truly empower clients with knowledge before any commitment.
KSquare’s guidance was top-tier. I felt informed and in control during the entire loan process. Truly reliable.
FAQ's
Frequenlty Asked Question
How does KSquare help in availing a loan against mutual funds?
KSquare simplifies the process by partnering with lenders and offering a smooth, digital journey from application to disbursal.
Are SIPs better than lump sum investments?
SIPs help average out market volatility over time, making them a safer and more consistent choice than lump sum investing.
How is the loan amount calculated?
The loan value is based on the mutual fund's NAV and the lender’s margin requirements. KSquare shows your eligible amount during application.
Are NFOs better suited for long-term investors?
NFOs are ideal for long-term investors who can wait for the fund to build performance and portfolio over time.
Will I get tax benefits through SIP investments?
Yes, SIPs in ELSS funds qualify for tax deductions under Section 80C up to ₹1.5 lakh annually.
Does KSquare provide research reports on NFOs?
Yes, KSquare offers fund highlights, investment strategy, and expert opinions to help you evaluate each NFO thoroughly.
Why should I consider investing in an NFO through KSquare?
KSquare offers expert analysis, transparent insights, and seamless access to promising NFOs aligned with your goals.
What if I fail to repay the loan on time?
In case of default, the lender may sell pledged mutual fund units. KSquare advises timely repayment to avoid any financial impact.